Search

Your search keyword '"Humphreys, Karen"' showing total 20 results
Start Over Author "Humphreys, Karen" Publication Year Range Last 10 years
20 results on '"Humphreys, Karen"'

7. Transcriptional regulation profiling reveals PPARA-mediated fatty acid oxidation as a novel therapeutic target in phospholamban R14del cardiomyopathy

Author

Harakalova, Magdalena, primary, Pei, Jiayi, additional, Maas, Renee, additional, Gaar-Humphreys, Karen, additional, Gho, Johannes, additional, Nagyova, Emilia, additional, Blok, Christian Snijders, additional, Adrichem, Iris van, additional, Es, René van, additional, Sepehrkhouy, Shahrzad, additional, Feyen, Dries, additional, Dungen, Noortje van den, additional, Lansu, Nico, additional, Calis, Jorg, additional, Kaaij, Niels van der, additional, de Jonge, Nicolaas, additional, Laake, Linda van, additional, Riele, Anneline ter, additional, Huibers, Manon, additional, de Weger, Roel, additional, Verhaar, Marianne C., additional, Tintelen, J. Peter van, additional, Vaz, Frederic, additional, Burgering, Boudewijn, additional, Mil, Alain van, additional, Buikema, Jan, additional, Vink, Aryan, additional, Karakikes, Ioannis, additional, Mercola, Mark, additional, Doevendans, Pieter AFM, additional, Sluijter, Joost, additional, Steenbeek, Frank van, additional, Cheng, Caroline, additional, Mokry, Michal, additional, and Asselbergs, Folkert, additional

Published
2022
Full Text
View/download PDF

9. Genetic Basis of Dilated Cardiomyopathy in Dogs and Its Potential as a Bidirectional Model

Author

Gaar-Humphreys, Karen R., primary, Spanjersberg, Talitha C. F., additional, Santarelli, Giorgia, additional, Grinwis, Guy C. M., additional, Szatmári, Viktor, additional, Roelen, Bernard A. J., additional, Vink, Aryan, additional, van Tintelen, J. Peter, additional, Asselbergs, Folkert W., additional, Fieten, Hille, additional, Harakalova, Magdalena, additional, and van Steenbeek, Frank G., additional

Published
2022
Full Text
View/download PDF

16. Butyrylated starch intake can prevent red meat-induced O6-methyl-2-deoxyguanosine adducts in human rectal tissue: a randomised clinical trial

Author

Le Leu, Richard K., primary, Winter, Jean M., additional, Christophersen, Claus T., additional, Young, Graeme P., additional, Humphreys, Karen J., additional, Hu, Ying, additional, Gratz, Silvia W., additional, Miller, Rosalind B., additional, Topping, David L., additional, Bird, Anthony R., additional, and Conlon, Michael A., additional

Published
2015
Full Text
View/download PDF

19. Impact of histone deacetylase inhibitors on microrna expression and cancer therapy: a review

Author

Ali, Saira R, Humphreys, Karen J, McKinnon, Ross A, and Michael, Michael Z

Subjects
cancer, Chemistry, Medicinal, Pharmacology & Pharmacy, histone deacetylase inhibitors, microRNAs
Abstract

Chromatin-modifying drugs, such as histone deacetylase inhibitors (HDACi), have shown potential as cancer therapeutics, either alone or in combination with other therapies. HDACi have the ability to reverse aberrant epigenetic modifications associated with cancer, namely dysregulated histone acetylation. There are currently three FDA approved HDACi; vorinostat, romidepsin, and panobinostat. Epigenetic modifications can regulate the expression of protein coding genes, and in addition can alter expression of microRNA (miRNA) genes. Many miRNAs play key roles in cell proliferation and apoptosis, and are commonly dysregulated in cancer states. A number of in vitro and in vivo studies have demonstrated the ability of chromatin-modifying drugs to alter miRNA expression, which may provide the basis for further investigation of miRNAs as therapeutic targets or as biomarkers of drug response. This review summarises findings from studies investigating the effects of HDACi on miRNA expression, as well as key clinical trials involving HDACi. Understanding how chromatin-modifying drugs epigenetically modulate miRNA genes provides further insight into the cellular mechanisms that deliver therapeutic responses, and may assist in refining treatment strategies. Drug Dev Res 76 : 296-317, 2015. (c) 2015 Wiley Periodicals, Inc. Refereed/Peer-reviewed

Published
2015

20. Functional high-throughput screen identifies microRNAs that promote butyrate-induced death in colorectal cancer cells.

Author

Ali SR, Humphreys KJ, Simpson KJ, McKinnon RA, Meech R, and Michael MZ

Abstract

The gut fermentation product butyrate displays anti-cancer properties in the human proximal colon, including the ability to inhibit proliferation and induce apoptosis in colorectal cancer (CRC) cells. A natural histone deacetylase inhibitor (HDACi), butyrate can alter histone acetylation patterns in CRC cells, and thereby regulate global gene expression, including the non-coding transcriptome and microRNAs (miRNAs). Dysregulated miRNA expression affects CRC development and progression; however, the interplay between miRNA activity and butyrate response remains to be elucidated. A high-throughput functional screen was employed to identify miRNAs that can act as enhancers of the anti-cancer properties of butyrate. Validation studies confirmed that several miRNAs, including miR-125b, miR-181a, miR-593, and miR-1227, enhanced apoptosis, decreased proliferation, and promoted cell-cycle arrest in the presence of butyrate. Pathway analyses of predicted miRNA target genes highlighted their likely involvement in critical cancer-related growth pathways, including WNT and PI3K signaling. Several cancer-associated miRNA targets, including TRIM29 , COX2 , PIK3R3 , CCND1 , MET , EEF2K , DVL3 , and NUP62 were synergistically regulated by the combination of cognate miRNAs and butyrate. Overall, this study has exposed the potential of miRNAs to act as enhancers of the anti-cancer effects of HDAC inhibition and identifies specific miRNAs that might be exploited for therapeutic benefit., Competing Interests: The authors declare no competing interests., (© 2022 The Author(s).)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results